当前位置: X-MOL 学术Theranostics › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma.
Theranostics ( IF 12.4 ) Pub Date : 2021-08-25 , DOI: 10.7150/thno.60350
Vida Mashayekhi 1 , Orsola Mocellin 1 , Marcel H A M Fens 2 , Gerard C Krijger 3 , Lodewijk A A Brosens 4 , Sabrina Oliveira 1, 2
Affiliation  

Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal types of cancer due to the relatively late diagnosis and the limited therapeutic options. Current treatment regimens mainly comprise the cytotoxic agents gemcitabine and FOLFIRINOX. These compounds have shown limited efficacy and severe side effects, highlighting the necessity for earlier detection and the development of more effective, and better-tolerated treatments. Although targeted therapies are promising for the treatment of several types of cancer, identification of suitable targets for early diagnosis and targeted therapy of PDAC is challenging. Interestingly, several transmembrane proteins are overexpressed in PDAC cells that show low expression in healthy pancreas and may therefore serve as potential targets for treatment and/or diagnostic purposes. In this review we describe the 11 most promising transmembrane proteins, carefully selected after a thorough literature search. Favorable features and potential applications of each target, as well as the results of the preclinical and clinical studies conducted in the past ten years, are discussed in detail.

中文翻译:

靶向用于诊断和治疗胰腺导管腺癌的有希望的跨膜蛋白。

由于相对较晚的诊断和有限的治疗选择,胰腺导管腺癌(PDAC)是最致命的癌症类型之一。目前的治疗方案主要包括细胞毒性药物吉西他滨和 FOLFIRINOX。这些化合物显示出有限的功效和严重的副作用,突出了早期检测和开发更有效、耐受性更好的治疗方法的必要性。尽管靶向治疗有望用于治疗多种类型的癌症,但确定适合 PDAC 早期诊断和靶向治疗的靶点具有挑战性。有趣的是,几种跨膜蛋白在 PDAC 细胞中过表达,在健康胰腺中表达较低,因此可能作为治疗和/或诊断目的的潜在靶点。在这篇综述中,我们描述了 11 种最有希望的跨膜蛋白,这些蛋白是经过彻底的文献检索后精心挑选的。详细讨论了每个靶点的有利特征和潜在应用,以及过去十年进行的临床前和临床研究的结果。
更新日期:2021-08-25
down
wechat
bug